The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index; none of the 22 sources its claims cite is checked for support yet.
Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues
Open accessAbstract
A combination of anti-CTLA-4 plus anti-PD-1/PD-L1 is the most effective cancer immunotherapy but causes high incidence of immune-related adverse events (irAEs). Here we report that targeting of HIF-1α suppressed PD-L1 expression on tumor cells and tumor-infiltrating myeloid cells, but unexpectedly induced PD-L1 in normal tissues by an IFN-γ-dependent mechanism. Targeting the HIF-1α/PD-L1 axis in tumor cells reactivated tumor-infiltrating lymphocytes and caused tumor rejection. The HIF-1α inhibitor echinomycin potentiated the cancer immunotherapeutic effects of anti-CTLA-4 therapy, with efficacy comparable to that of anti-CTLA-4 plus anti-PD-1 antibodies. However, while anti-PD-1 exacerbated irAEs triggered by ipilimumab, echinomycin protected mice against irAEs by increasing PD-L1 levels in normal tissues. Our data suggest that targeting HIF-1α fortifies the immune tolerance function of the PD-1/PD-L1 checkpoint in normal tissues but abrogates its immune evasion function in the tumor microenvironment to achieve safer and more effective immunotherapy.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Targeting HIF-1α with liposomal echinomycin (LEM) suppresses PD-L1 in the tumor microenvironment and reactivates antitumor immunity, while unexpectedly inducing PD-L1 in normal tissues via IFN-γ. This differential regulation potentiates anti–CTLA-4 therapy without the irAE exacerbation seen with anti–PD-1.
Key findings
- LEM reduced PD-L1 on tumor cells and tumor-infiltrating myeloid cells (M-MDSCs, PMN-MDSCs, and CD11b+CD11c+ cells, ~90% of which were F4/80+ TAMs), increased IFN-γ+CD8+ (Tc1) and IFN-γ+CD4+ (Th1) TILs, and inhibited tumor growth in immunocompetent but less so in immunodeficient mice.
- LEM potentiated anti–CTLA-4 (9D9) therapy in 4T1, E0771, and MC38 models, with efficacy comparable to anti–CTLA-4 plus anti–PD-1; optimal efficacy required CD8+, NK, and CD4+ cells, with CD8+ cells most critical.
- In normal tissues, LEM induced PD-L1 in liver, kidney, and intestine by an IFN-γ–dependent mechanism; in CTLA4h/h-KI mice, LEM protected against ipilimumab-induced intestinal leakage, and adding anti–IFN-γ increased the frequency of mice with leakage from 7.7% to 20.0%.
- Anti–PD-1 abrogated LEM’s protection against ipilimumab-induced GI irAEs, whereas LEM protected mice by increasing normal-tissue PD-L1; the paper notes dual checkpoint blockade causes severe irAEs in 50%–90% of patients depending on setting.
Methods
- Syngeneic mouse tumor models: 4T1 and E0771 breast cancer and MC38 colon adenocarcinoma in BALB/c, C57BL/6, and NSG mice; genetic tools included shHif1a, shPdl1, and conditional Hif1a knockout in T cells.
- Treatments: liposomal echinomycin (LEM) i.v. at 0.15–0.25 mg/kg; anti–mouse CTLA-4 (9D9), anti–PD-1 (RMP1-14), anti–IFN-γ (XMG1.2), and depleting CD4/CD8/NK antibodies; readouts included flow cytometry, immunofluorescence, histology, and FITC-dextran intestinal permeability.
- GI irAE model: 10-day-old human CTLA4-knockin mice received ipilimumab i.p. on days 10, 13, 16, and 19; FITC-dextran assay on day 32. Statistics used t tests, 1-way/2-way ANOVA with Sidak’s post hoc test, and Pearson correlation in Prism 8, with P < 0.05 significant.
Limitations
- Stated: adult tumor-bearing mice tolerated high-dose anti–CTLA-4 without significant irAEs, so the irAE studies relied on young CTLA4h/h-KI mice.
- Stated: it is unclear whether LEM promotes Tc1 expansion in vivo by cell-intrinsic HIF-1α targeting or indirectly by reducing regulatory T cells.
- Evident: all efficacy and toxicity data are preclinical mouse models; no human clinical outcomes or patient data are reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 22 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In a second breast cancer model, E0771, the therapeutic effects of LEM were also more pronounced in immune-competent mice (Figure 2C).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > Immunotherapeutic effect of LEM.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LEM significantly inhibited 4T1 growth in both immunocompetent (BALB/c) and immunodeficient (NSG) recipients compared with each strain’s respective vehicle control (Figure 2B).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > Immunotherapeutic effect of LEM.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LEM did not further suppress sh-Pdl1 E0771 tumor growth in C57BL/6 (Figure 3C) or NSG (Figure 3D) recipients.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 in tumor cells by targeting the HIF-1α/PD-L1 axis.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there was a marked reduction in PD-L1 expression in the tumors of LEM-treated mice.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > Targeting HIF-1α suppresses PD-L1 expression in the TME.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LEM more effectively inhibited sh-Scr E0771 tumor growth in C57BL/6 (Figure 3C) compared with NSG (Figure 3D) recipients”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 in tumor cells by targeting the HIF-1α/PD-L1 axis.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Under basal conditions, we found that knockdown of Hif1a reduced PD-L1 protein expression (Figure 1, G–J).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > Targeting HIF-1α suppresses PD-L1 expression in the TME.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Both cell lines expressed HIF-1α and PD-L1 protein (Figure 1, A and B; see complete unedited blots in the supplemental material)”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > Targeting HIF-1α suppresses PD-L1 expression in the TME.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“4T1 growth was more significantly inhibited in immunocompetent mice than in immunodeficient mice”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > Immunotherapeutic effect of LEM.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As with E0771, all therapeutic effects required immune competence (Figure 2D).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > Immunotherapeutic effect of LEM.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In C57BL/6, but not NSG recipients, genetic depletion of Hif1a (sh-Hif1a) in E0771 cells significantly inhibited tumor growth compared with E0771 transduced with scrambled shRNA (sh-Scr) in mice of the same respective strains (Figure 3B).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 in tumor cells by targeting the HIF-1α/PD-L1 axis.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 30
- Probably not a substantial claim. 15
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of Pdl1 (sh-Pdl1) in E0771 cells also inhibited tumor growth in C57BL/6, but not NSG, recipients (Figure 3B)”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 in tumor cells by targeting the HIF-1α/PD-L1 axis.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“TNF-α was unaffected by the therapies in CD4+ TILs, although we observed increased TNF-α+CD8+ TILs in groups receiving 9D9 (Supplemental Figure 5, E and F).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of tumor-infiltrating NK cells expressing granzyme B and perforin were decreased and increased, respectively, in mice treated with 9D9 alone (Supplemental Figure 5, K and L).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The inflammation was largely abrogated by LEM, as mice treated with ipilimumab plus LEM for the most part exhibited normal intestinal pathology (Figure 8F).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM protected ipilimumab-induced irAEs in human CTLA4–knockin mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The drug treatments had minimal impact on CD4+ TIL expression of CTLA-4 (Supplemental Figure 5B).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Conditional knockout of Hif1a in T cells did not phenocopy the effects of LEM on PD-L1 induction in the liver, but PD-L1 induction was preserved regardless of the mouse genotype (Supplemental Figure 14).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM induces PD-L1 expression to limit anti–CTLA-4–induced T cell infiltration in irAE target organs.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Annexin V staining revealed more apoptotic CD8+ and CD4+ TILs in tumors of 9D9-treated mice compared with vehicle, and adding LEM appeared to repress this effect in CD8+ TILs (Figure 6C).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“9D9 significantly increased and decreased the frequencies of effector and memory CD8+ T cells in the tumors, respectively (Supplemental Figure 6).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared with vehicle, all treatments increased the frequencies of both IFN-γ+CD8+ (Tc1) and IFN-γ+CD4+ (Th1) subsets, although the highest frequencies of Tc1 were observed in mice receiving 9D9 plus LEM (Figure 5, E and F).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The same trend was seen for CD4+ TILs, although the difference between the 9D9 and 9D9 plus LEM groups was not significant (Figure 6D).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“None of the therapies significantly impacted frequencies of tumor-infiltrating Treg or Th17 cells, except for a modest decrease in Tregs for groups receiving 9D9 (Supplemental Figure 5, I and J).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Roughly one-fifth of CD4+ TILs were granzyme B+, which was not significantly affected by drug treatments (Figure 6G).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we observed significant inhibition of tumor growth by LEM or 9D9 monotherapy compared with vehicle, while the greatest inhibition was achieved by 9D9 plus LEM or RMP1-14 (Figure 4, C and D).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > HIF-1α inhibition potentiates anti–CTLA-4 immunotherapy.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“E0771 mice treated with 9D9 had higher expression of exhaustion marker PD-1 on CD8+ TILs compared with vehicle, which was reversed by LEM (Figure 6A).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LEM alone did not stimulate increased infiltration of T or NK cells in the tissues with PD-L1 expression (Figure 7, B–D, and Supplemental Figure 11), but led to a modest increase in IFN-γ detected in the serum (Supplemental Figure 12).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM induces PD-L1 expression to limit anti–CTLA-4–induced T cell infiltration in irAE target organs.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These studies revealed that optimal efficacy required all 3 cell types, with CD8+ cells being the most critical, followed by NK and CD4+ cells (Figure 6I).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the anti–IFN-γ neutralizing mAb XMG1.2, which abrogated PD-L1 induction by 9D9 plus LEM treatment and increased T cell infiltration in the kidneys and liver (Figure 7, B–D).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM induces PD-L1 expression to limit anti–CTLA-4–induced T cell infiltration in irAE target organs.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the frequency of T cells as well as those of Tc1 and Th1 expanded in the spleen of mice that received 9D9 plus LEM treatment (Figure 7, E–G).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM induces PD-L1 expression to limit anti–CTLA-4–induced T cell infiltration in irAE target organs.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results demonstrate that HIF-1α controls PD-L1 expression in E0771 cells and that echinomycin reduced PD-L1 by inhibiting the HIF-1α/PD-L1 axis.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > Targeting HIF-1α suppresses PD-L1 expression in the TME.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the immunotherapeutic effects of pharmacological HIF-1α inhibition in the context of anti–CTLA-4 are multiple-cell dependent, but primarily depend on CD8+ T cells.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“HIF-1α is generally inactivated in normal tissues but frequently stabilized in tumor cells regardless of oxygen tension (49, 50).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here, we showed that targeting HIF-1α not only overcomes immune evasion in the TME, but also fortifies the immune tolerance checkpoint in normal tissues.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The current approach that overcomes tumor evasion of host immunity also disables the immune tolerance checkpoint, leading to significant irAEs, particularly when used in conjunction with anti–CTLA-4 antibodies.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results show that, in addition to tumor cells, in vivo HIF-1α inhibition can also suppress PD-L1 on tumor-infiltrating myeloid cells, and these effects persist in the context of anti–CTLA-4 therapy.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM inhibits PD-L1 on tumor cells and tumor-infiltrating myeloid cells.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The GI tract is the most frequent target of irAEs (31).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Results > LEM protected ipilimumab-induced irAEs in human CTLA4–knockin mice.
What the sources say
- Not checked yetcites [31] source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our data suggest that targeting HIF-1α fortifies the immune tolerance function of the PD-1/PD-L1 checkpoint in normal tissues but abrogates its immune evasion function in the tumor microenvironment to achieve safer and more effective immunotherapy.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“On the other hand, studies by Johnson and colleagues found HIF-1α to be essential for myeloid cell–mediated inflammation (40).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
What the sources say
- Not checked yetcites [40] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“While HIF-1α has been shown to be involved in degradation of Foxp3 and induce the Th17 phenotype (26)”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
What the sources say
- Not checked yetcites [26] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Sample sizes were chosen with adequate statistical power on the basis of the literature and past experience.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Methods > Statistics.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Sitkovsky’s group originally demonstrated the first in vitro evidence that hypoxia is immunosuppressive for T cells (36)”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
What the sources say
- Not checked yetcites [36] source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All experiments were replicated at least twice with similar results.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Methods > Statistics.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the data presented herein revealed a cancer cell–intrinsic inhibition of PD-L1 and normal tissue cell–extrinsic induction of PD-L1 by LEM.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“According to Doedens et al., HIFs enhance the effector responses of CD8+ T cells to persistent antigen (42).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
What the sources say
- Not checked yetcites [42] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The induced PD-L1 is causatively associated with reduction in inflammation and intestinal leakage induced by anti–CTLA-4 antibodies, as it is abrogated by anti–PD-1 antibodies.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All procedures involving experimental animals were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Maryland School of Medicine.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Methods > Study approval.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“On day 6 after transplantation, mice were assigned to treatment groups such that comparable initial mean tumor volumes between experimental and control groups were achieved.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Methods > Tumor models.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“We have reported that echinomycin effectively eliminated leukemia stem cells (34).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
What the sources say
- Not checked yetcites [34] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together, these 2 activities provide what we believe is the first example in cancer immunotherapy of an approach that abrogates the PD-1–PD-L1 checkpoint in the TME to eliminate immune evasion by cancer cells, while fortifying its immune tolerance checkpoint activity in normal tissues.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In T cells, HIF-1α is transiently stabilized in T cells following TCR activation (41), and plays an important role in regulating Treg and Th17 balance (26).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
What the sources say
Strength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“its function in inducing the Th1 phenotype has also been reported (51).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
What the sources say
- Not checked yetcites [51] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast to anti–PD-1, LEM not only further enhanced anti–CTLA-4–induced PD-L1 in normal tissue, but also allowed PD-L1 to signal through PD-1 to supercharge the immune tolerance checkpoint function.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“All animal experiments were conducted according to guidelines established by the NIH Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011).”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Methods > Study approval.
What the sources say
- Not checked yetcites National Academies Press, 2011
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Appropriate statistical tests were selected on the basis of whether the data with outlier deletion was normally distributed by using the D’Agostino & Pearson normality test.”
§ Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues > Methods > Statistics.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Clinical development of echinomycin for solid tumors has met with minimal success.
“However, clinical development of echinomycin for solid tumors has met with minimal success.”
The paper relies on this without support.
The current approach that overcomes tumor evasion of host immunity also disables the immune tolerance checkpoint, leading to significant irAEs, particularly when used in conjunction with anti–CTLA-4 antibodies.
“However, the current approach that overcomes tumor evasion of host immunity also disables the immune tolerance checkpoint, leading to significant irAEs, particularly when used in conjunction with anti–CTLA-4 antibodies.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bailey, Liu, et al. in this issue demonstrate that targeting HIF-1α abrogated PD-L1–mediated immune evasion by suppressing PD-L1 expression on malignant and myeloid regulatory cells, causing tumor rejection.”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [24]
In the citing paper
“Bailey, Liu, et al. confirmed these results (24).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [24]
In the citing paper
“Importantly, HIF-1α inhibition potentiated immunotherapeutic effects of anti–CTLA-4 therapy in experimental models.”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [24]
In the citing paper
“HIF-1α inhibition in vivo downregulated PD-1 expression, upregulated cytolytic effector molecules granzyme B and perforin, and decreased apoptosis in TILs in the tumor microenvironment.”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [24]
In the citing paper
“Promotion of immune tolerance by differential regulation of PD-L1 in normal and cancer tissues is an important approach for safer and more successful immunotherapy (24).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [24]
In the citing paper
“The authors also reported an interesting observation; although HIF-1α inhibition blocked PD-L1 expression at the tumor site, it induced PD-L1 in normal tissues.”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [24]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“Discussion HIF-1α inhibition is an area of active investigation in cancer therapy (32, 33).”
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723 · cited 3×
“In terms of therapeutic efficacy, anti–CTLA-4 plus anti–PD-1 combination therapy is considered the most effective immunotherapy strategy (5).”
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066 · cited 1×
“For example, hypoxia, which is one of the major hallmarks distinguishing solid tumors from normal tissues (22), was reportedly responsible for inducing PD-L1 in tumor (23) and myeloid cells (12) via HIF-1α.”
HIF-1α is essential for myeloid cell-mediated inflammation
Cramer, T., Yamanishi, Y., Clausen, B. E., Förster, I., Pawlinski, R., Mackman, N., Haase, V. H., Jaenisch, R., Corr, M., Nizet, V., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00154-5 · Cited by 2,046
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,414
Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 706
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2714 · Cited by 660 · cited 1×
“, HIFs enhance the effector responses of CD8+ T cells to persistent antigen (42).”
Wang, C., Thudium, K. B., Han, M., Wang, X., Huang, H., Feingersh, D., Garcia, C., Wu, Y. M., Kuhné, M. R., Srinivasan, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0040 · Cited by 611
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521 · cited 1×
“showed that selective HIF-1α targeting in T cells inhibited IFN-γ and granzyme B production in CD8+ TILs (43).”
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 489
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Luoma, A. M., Suo, S., Williams, H. L., Sharova, T., Sullivan, K., Manos, M., Bowling, P., Hodi, F. S., Rahma, O., Sullivan, R. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.001 · Cited by 484
Caldwell, C. C., Kojima, H., Lukashev, D., Armstrong, J., Farber, M., Apasov, S. G., & Sitkovsky, M. V. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6140 · Cited by 420
Targeting HIF1α Eliminates Cancer Stem Cells in Hematological Malignancies
Wang, Y., Liu, Y., Malek, S. N., Zheng, P., & Liu, Y. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.02.006 · Cited by 410 · cited 1×
“We have reported that echinomycin effectively eliminated leukemia stem cells (34).”
Self-citationB7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis
Mazanet, M. M., & Hughes, C. C. W. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3581 · Cited by 333
Zerdes, I., Matikas, A., Bergh, J. C. S., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 305
Non-Canonical Mechanisms Regulating Hypoxia-Inducible Factor 1 Alpha in Cancer
Iommarini, L., Porcelli, A. M., Gasparre, G., & Kurelac, I. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00286 · Cited by 231
Kojima, H., Gu, H., Nomura, S., Caldwell, C. C., Kobata, T., Carmeliet, P., Semenza, G. L., & Sitkovsky, M. V. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052706699 · Cited by 224
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2019) · Cell · doi:10.1016/j.cell.2019.01.008 · Cited by 223
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Belikoff, B., Schreiber, T. H., Sethumadhavan, S., Abbott, R., Philbrook, P., Thayer, M., Shujia, D., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1189-3 · Cited by 211
Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment
Xiong, H., Mittman, S., Rodriguez, R., Москаленко, М., Pacheco-Sanchez, P., Yang, Y., Nickles, D., & Cubas, R. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3208 · Cited by 199
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190
Nakamura, H., Makino, Y., Okamoto, K., Poellinger, L., Ohnuma, K., Morimoto, C., & Tanaka, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7592 · Cited by 158
Hypoxia-inducible factors in cancer stem cells and inflammation
Peng, G., & Liu, Y. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.003 · Cited by 127
Self-citationDu, X., Liu, M., Su, J., Zhang, P., Tang, F., Ye, P., Devenport, M., Wang, X., Zhang, Y., Liu, Y., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0012-z · Cited by 123
Self-citationCutting Edge: Hypoxia-Inducible Factor 1 Negatively Regulates Th1 Function
Shehade, H., Acolty, V., Moser, M., & Oldenhove, G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402552 · Cited by 98
Yang, H., Chou, H., Gu, X., Wang, L., Brown, K. E., Fung, J. J., Lu, L., & Qian, S. (2009) · Hepatology · doi:10.1002/hep.23202 · Cited by 71
Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102278 · Cited by 44 · cited 2×
“In our studies of breast cancer, we found that reformulating echino-mycin with liposomes (LEM) enabled potent therapeutic effects in orthotopic xenograft mouse models of triple-negative breast cancer, including primary tumor growth and metastasis in the MDA-MB-231 and SUM-159 models (35).”
Self-citationHatfield, S. M., & Sitkovsky, M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052934 · Cited by 31
Flagged first, then by citations
2 of the 58 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 909
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Yu, X., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 313
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Q., Han, J., Yang, Y., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070961 · Cited by 255
Regulatory T cells in immune checkpoint blockade antitumor therapy
Zhang, A., Fan, T., Liu, Y., Yu, G., Li, C., & Jiang, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02156-y · Cited by 174
Self-citationRibonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer
Zuo, Z., Zhou, Z., Chang, Y., Liu, Y., Shen, Y., Li, Q., & Zhang, L. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.11.022 · Cited by 132
Self-citation
Metadata
- Authors
- Bailey, C. M., Liu, Y., Liu, M., Du, X., Devenport, M., Zheng, P., Liu, Y., & Wang, Y.
- Affiliations
- University of Maryland, Baltimore (US)
- Corresponding author
- Liu, Yang
- Wang, Yin
- Venue
- Journal of Clinical Investigation
- Published
- 2022-05-02
- Volume
- 132
- Issue
- 9
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC9057613
- OpenAlex
- W4214881895
- Semantic Scholar
- 61d954ba1fe3c4cba513f816261e83f90b00fc87
- Cited by
- 151
- References
- 58
- Citations by year
- 2026: 34 · 2025: 45 · 2024: 38 · 2023: 24 · 2022: 10
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health (CA171972, CA183030, CA219150, CA227671)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- HIF-1α, PD-L1, immune evasion, tumor microenvironment, immune-related adverse events, CTLA-4, PD-1/PD-L1 immune checkpoint, echinomycin, interferon-gamma, tumor-infiltrating myeloid cells, tumor-infiltrating lymphocytes, cancer immunotherapy
- MeSH terms
- Animals, Echinomycin, Immune Tolerance, Neoplasms, Lymphocytes, Tumor-Infiltrating, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Immune Evasion, Tumor Microenvironment, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
